Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027
Covered in this story
Call it yourself
No calls on $LTGO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Latigo Biotherapeutics, Inc. →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.